Open an account

Cadrenal Therapeutics

CVKD · NASDAQ

$1.04−$0.02 (−1.89%)TodayMarket closed ·
Prev close $1.06

About CVKD

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 5 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.

Employees
5
Headquarters
Ponte Vedra, Florida
Listed
Jan 20, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
cadrenal.com

CVKD key statistics

Market cap
3.71M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
234.03K
Volume
49.84K
Open price
$1.04
High today
$1.10
Low today
$1.00
52 Week high
$14.21
52 Week low
$0.8163

Cadrenal Therapeutics (CVKD) at a glance

As of Oct 20, 2026, Cadrenal Therapeutics (CVKD) shares are priced at $1.04, giving the company a market cap of 3.71M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.00 and $1.10. The current price is 4.0% above the day's low and 5.5% below its high.

Volume so far is 49.84K shares, below the average of 234.03K shares a day.

Over the past year Cadrenal Therapeutics has ranged from $0.8163 to $14.21, and now sits 2% of the way up that range.

Cadrenal Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.14 per share against an estimate of -$1.45.

The average analyst price target is $14.28, 1273.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $14.28
Low
$12.12
Now
$1.04
High
$17.85

CVKD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 24.7% on average.

  1. Q3 FY24: reported -$2.18 per share against an estimate of -$1.97
  2. Q4 FY24: reported -$2.74 per share against an estimate of -$1.75
  3. Q1 FY25: reported -$2.09 per share against an estimate of -$1.67
  4. Q2 FY25: reported -$1.87 per share against an estimate of -$1.63
  5. Q3 FY25: reported -$1.31 per share against an estimate of -$1.56
  6. Q4 FY25: reported -$1.43 per share against an estimate of -$1.19
  7. Q1 FY26: reported -$1.04 per share against an estimate of -$1.65
  8. Q2 FY26: reported -$1.14 per share against an estimate of -$1.45

CVKD news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

  • Press releaseBusiness Wire

    Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

  • Press releaseBusiness Wire

    Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

  • Press releaseBusiness Wire

    Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

  • Press releaseBusiness Wire

    Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

  • Press releaseBusiness Wire

    Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as Cadrenal Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.